Strategic Focus on High Unmet Medical Needs and Pipeline Advancements
FOSTER CITY, Calif., February 20, 2024--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:
Gilead Sciences said on Thursday enrollments to test its cancer drug, magrolimab, on solid tumors had been paused globally, a week after the U.S. regulator put some studies on hold following increased risk of patient deaths. The U.S. drugmaker had also said it would stop testing magrolimab on all forms of blood cancers and review its safety across other studies such as those in patients with colon and breast cancers. The drug is an antibody treatment that blocks a type of protein, called CD47, which helps damaged cells avoid destruction by the immune system.